You are here: Home

 Welcome to Elite Pharmaceuticals

 
 

Elite Pharmaceuticals, Inc. specializes in the development of oral controlled release products, such as delayed, sustained, targeted and pulsatile release tablets, pellets, capsules, granules and powders.  The Company’s primary focus is in the therapeutic areas of pain management, allergy, cardiovascular and infection.

 
    The Rodman & Renshaw 16th Annual Global Investment Conference

Live presentation on September. 9, 2014 at 2:55 PM Eastern
replay available until December 18, 2014
View Webcast  

 


Recent Press Releases:
12/16/2014 Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation

12/3/2014 ELITE PHARMACEUTICALS REPORTS SUCCESSFUL PIVOTAL BIOEQUIVALENCE STUDY FOR ABUSE-DETERRENT OXYCODONE PRODUCT ELI-201

11/14/2014 Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015
Revenues increase by 8%
Conference Call Scheduled for Wednesday, November 19 at 11:00 AM EST


10/24/2014 ELITE PHARMACEUTICALS ANNOUNCES NEW MANAGEMENT APPOINTMENTS

9/9/2014 ELITE PHARMACEUTICALS RELEASES POSITIVE TOP LINE HUMAN ABUSE LIABILITY DATA FOR ELI-200, AN OPIOID ABUSE DETERRENT PRODUCT
HAL study compared subjective effects of drug liking, drug high and good drug effects between ELI-200 and the comparator formulation in non-dependent recreational drug users


 

Elite Pharmaceuticals, Inc. 165 Ludlow Ave., Northvale, NJ 07647    Phone:  201-750-2646  Fax:  201-750-2755 
E Mail:  webmaster@elitepharma.com